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IL-6 Blockade Attenuates the Development of Murine
Sclerodermatous Chronic Graft-Versus-Host Disease
Doanh Le Huu1, Takashi Matsushita1, Guihua Jin1, Yasuhito Hamaguchi1, Minoru Hasegawa1,
Kazuhiko Takehara1 and Manabu Fujimoto1
Systemic sclerosis (scleroderma) is a connective tissue disease characterized by excessive extracellular matrix
deposition in the skin and visceral organs. Serum IL-6 levels are reported to be elevated in human scleroderma
and chronic graft-versus-host disease (cGVHD) patients. IL-6 blockade using anti-IL-6 receptor mAb (anti-IL-6R
mAb) results in amelioration of the pathologic symptoms of some autoimmune diseases such as rheumatoid
arthritis and juvenile idiopathic arthritis. In this study, we examined the effects of anti-IL-6R mAb on
either prevention or treatment of murine sclerodermatous cGVHD (Scl-cGVHD). We found that serum IL-6 levels
in Scl-cGVHD mice gradually increased after bone marrow transplantation. Administration of anti-IL-6R
mAb attenuated the development of severe Scl-cGVHD and fibrosis and resulted in an increase in
CD4þCD25þFoxP3þ regulatory T cells. However, treatment of established Scl-cGVHD with anti-IL-6R mAb
showed no effects on disease severity. The effects of anti-IL-6R mAb were mostly inhibited by anti-CD25
mAb. Together, our results indicate that IL-6 has an important role in the pathogenesis of Scl-cGVHD.
IL-6 blockade may be an effective approach for preventing Scl-cGVHD and treating cGVHD and scleroderma in
humans.
Journal of Investigative Dermatology (2012) 132, 2752–2761; doi:10.1038/jid.2012.226; published online 19 July 2012
INTRODUCTION
Systemic sclerosis (SSc) is a connective tissue disease
characterized by excessive extracellular matrix deposition
in the skin and visceral organs (Varga and Abraham, 2007).
The etiology and pathogenesis of SSc are so far unknown
(Katsumoto et al., 2011). Chronic graft-versus-host disease
(cGVHD) emerges from alloreactive reactions between
donor-derived immune cells and host cell populations,
and donor T cells have a major role in the pathogenesis
of this disease. On the basis of clinical similarities
between sclerodermatous cGVHD (Scl-cGVHD) and SSc-
transplantation of B10.D2 (H-2d) bone marrow and spleno-
cytes across minor histocompatibility loci into sublethally
irradiated BALB/c (H-2d) recipients has become a well-
established animal model for human Scl-cGVHD and SSc
(Jaffee and Claman, 1983; Toshiyuki, 2005; Ferrara and
Reddy, 2009).
IL-6 is a widely expressed effector cytokine that is pro-
duced by activated T cells, B cells, and macrophages (Scheller
and Rose-John, 2006). IL-6 inhibits the induction of TGF-b-
induced regulatory T cells (Tregs), whereas IL-6 induces Th17
differentiation in the presence of TGF-b (Bettelli et al., 2006).
Of note, it has been shown that the absence of Tregs results in
IL-6 production, which leads to the development of GVHD-
associated autoimmunity (Chen et al., 2007).
The serum IL-6 levels were elevated in patients with diffuse
SSc (Stuart et al., 1995; Hasegawa et al., 1998; Sato et al., 2001;
Matsushita et al., 2006). In this regard, serum IL-6 levels may be
a useful indicator of disease activity in SSc (Stuart et al., 1995;
Hasegawa et al., 1998, 2011; Scala et al., 2004).
Blockade of IL-6 signaling by anti-IL-6 receptor mAb (anti-
IL-6R mAb) has positive effects on several experimental
inflammatory diseases, such as experimental autoimmune
encephalomyelitis, polymicrobial sepsis, and autoimmune kidney
disease (Mihara et al., 1998; Serada et al., 2008; Mukaino et al.,
2010). Furthermore, administration of anti-IL-6R mAb was effec-
tive in patients with autoimmune diseases such as rheumatoid
arthritis and juvenile idiopathic arthritis (Nishimoto et al., 2008).
For these reasons, we examined the relationship between IL-6
and Scl-cGVHD development, and the effects of anti-IL-6R
mAb on murine Scl-cGVHD initiation and progression.
RESULTS
Serum IL-6 gradually increases during the course of cGVHD
development
Alteration of skin cytokine messenger RNA (mRNA) expres-
sion in murine Scl-cGVHD has been reported, with a
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mixed Th1/Th2-like cytokine profile present in early fibrosis,
characterized by an initial Th1-like predominance that pre-
ceded a Th2-like profile (Zhou et al., 2007).
To investigate how serum inflammatory cytokines are
altered during the course of Scl-cGVHD, IL-6, IL-10, mono-
cyte chemotactic protein-1 (MCP-1), IFN-g, tumor necrosis
factor-a (TNF-a), and IL-12p70 levels were measured by
Cytometric Bead Array (CBA) on days 7, 14, 21, 28, and 35
after bone marrow transplantation (BMT; Figure 1a). Although
TNF-a and IFN-g reached a peak at day 28 after BMT, the
level of IL-6 gradually increased throughout the 35-day
examination period after BMT (Figure 1a). Whereas IL-12
and IL-10 did not change during cGVHD development,
MCP-1 increased 7 days post transplantation (Figure 1a), with
Po0.01 compared with BALB/c mice without BMT (Data not
shown).
Blockade of IL-6/IL-6R interactions after administration
of anti-IL-6R mAb
To determine whether blockade of IL-6R would result in an
alteration in the levels of circulating inflammatory cytokines,
we blocked IL-6 signaling using a mAb that binds to both
membrane and soluble components of the IL-6R. Either anti-
IL-6R mAb (MR16-1) or control rat IgG was injected into
recipients on the day of BMT. Serum samples were harvested
on day 7 following BMT for examination of proinflammatory
cytokine levels. These data revealed a significant increase in
IL-6 levels in the MR16-1-treated group (Figure 1b) but no
significant differences in the rest of cytokine levels compared
with the control group (Figure 1b). A similar increase in
serum IL-6 levels after MR16-1 injection had been previously
reported and was postulated to result from decreased
cytokine clearance as a consequence of circulating IL-6
being unable to bind to IL-6Rrs (Uchiyama et al., 2008; Chen
et al., 2009).
Blockade of IL-6 attenuated cGVHD severity in a preventive
model of Scl-cGVHD, but not in a therapeutic model
The current study showed that serum IL-6 levels gradually
increased during Scl-cGVHD development. Thus, we con-
ducted studies to determine whether treatment with
MR16-1 would result in prevention or in treatment of
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Figure 1. Changes in serum inflammatory cytokines levels during development of sclerodermatous chronic graft-versus-host disease (Scl-cGVHD). BALB/c
(H-2d) recipients were irradiated (800 cGy) and transplanted with B10.D2 (H-2d) donor 10106 T-cell-depleted bone marrow (TCD-BM) and 10 106
unfractionated splenocytes. (a) Serum samples were collected every 7 days after bone marrow transplantation (BMT). IL-12p70, tumor necrosis factor-a (TNF-a),
IFN-g, monocyte chemotactic protein-1 (MCP-1), IL-10, and IL-6 levels were measured by Cytometric Bead Array. (b) Allogeneic BMT recipients were treated
with MR16-1 (anti-IL-6R mAb,&) or with control rat IgG (’) on day 0 at a dose of 2mg per mouse. Seven days after BMT, serum IL-6, IL-10, MCP-1, IFN-g,
TNF- a, and IL-12p70 concentrations were measured by Cytometric Bead Array. Each value indicates mean (±SEM) results from three to four mice. **Po0.01.
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cGVHD. During preventive application of MR16-1, both
treated and control recipients showed similar early declines
and recovery in body weight (Figure 2a). However, once
skin lesions developed, MR16-1-treated mice experienced
less body weight loss than controls, with weight loss of
10±0.02% vs. 21±0.02% at day 30 and 14±0.01%
vs. 26±0.01% at day 42 (Figure 2a, P¼0.01). Similarly,
MR16-1-treated mice developed less skin disease, as
evidenced by their improved skin score curve (Figure 2b).
For example, the average control versus MR16-1 skin score
was 4.76±0.40 vs. 2.95±0.42 at day 30, and 5.74±0.52 vs.
3.77±0.56 at day 42 after BMT, respectively (Figure 2b,
Po0.05).
TGF-b is a key mediator of tissue fibrosis in SSc and
includes three mammalian isoforms (Ihn, 2008). TGF-b1 is
the primary isoform responsible for collagen upregulation
leading to skin fibrosis (McCormick et al., 1999). In our
MR16-1 preventive model, plasma TGF-b1 levels were found
to be elevated in the control group relative to the MR16-1-
treated group (Figure 2d). In contrast, there were no
significant differences in body weight or skin score when
MR16-1 was administered therapeutically on day 25 after
BMT (Figure 2e and f).
The observed trends in skin disease were also verified by
histopathology. Skin histopathological scores, dermal thick-
ness, skin total soluble collagen, and collagen deposition of
skin, lung, and liver were measured as described in Materials
and Methods. In the preventive model, histopathological
scores, dermal thicknesses, skin soluble collagen, and fibrosis
area in skin, lung, and liver were lower in the MR16-1-treated
group than in the control group (Po0.05; Figure 3b, d, f,
and g). However, in the therapeutic model, the MR16-1-
treated group had scores indistinguishable from the control
group (Figure 3c and e).
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Figure 2. MR16-1 treatment attenuated chronic graft-versus-host disease (cGVHD) severity in a preventive model but did not alter in a therapeutic model.
Preventive model: recipients were treated with MR16-1 (n) or control (’) on day 0 at a dose of 2mg per mouse and then weekly at a dose of 0.5mg per
mouse. (a) Body mass changes and (b) skin scores were assessed every 3 days. (c) Representative photographs were taken on day 42 after bone marrow
transplantation (BMT). (d) Plasma TGF-b1 level was measured by ELISA 42 days after BMT. Therapeutic model: recipients were treated with MR16-1 (n) or
control (’) on day 25 at a dose of 2mg per mouse and then weekly at a dose of 0.5mg per mouse. (e) Body mass changes and (f) skin scores were assessed every
3 days. Each value indicates mean (±SEM) results from five mice. *Po0.05.
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Attenuation of cGVHD by blockade of IL-6 is correlated
with increased Treg numbers
As IL-6 inhibits the differentiation of Tregs that negatively
regulate some autoimmune diseases including GVHD
(Scheller and Rose-John, 2006; Serada et al., 2008), we
analyzed the number of Tregs (CD4þCD25þFoxp3þ T cells)
in preventive model. In both early-stage (14 days after BMT)
and late-stage (42 days after BMT) disease, an increase in
Treg numbers was found in the MR16-1-treated group
compared with the control group (P¼0.03, Figure 4a and
b). In our therapeutic model, Treg numbers were no different
between control and MR16-1 groups at day 57 (Figure 4c).
Regulatory B cells (IL-10-producing B cells) are able to
influence the progression of some inflammatory diseases such
as contact hypersensitivity, rheumatoid arthritis, and ence-
phalomyelitis (Watanabe et al., 2007; Lampropoulou et al.,
2008; Matsushita et al., 2008; Fujimoto, 2010). Splenic
regulatory B cells have been recently identified within a
unique CD1dhiCD5þ B-cell subset (Yanaba et al., 2008). To
determine whether B cells and CD1dhiCD5þ B cells change
after IL-6 blockade, we analyzed B-cell and CD1dhiCD5þ
B-cell numbers in MR16-1-treated and control mAb-treated
mice. MR16-1 treatment had no effects on total B-cell and
CD1dhiCD5þCD19þ B-cell numbers in either our preventive
model or in our therapeutic model (Figure 4e–g). Splenic
IL-10-producing B cells were also analyzed, but there was no
significant difference in the frequency of IL-10-producing B
cells between MR16-1-treated and control groups (Figure 5a
and b).
TNF-a has a role in all phases of GVHD pathophysiology
to mediate both direct tissue damage and indirect tissue
damage caused by cytotoxic lymphocytes (Levine, 2011). To
investigate whether TNF-a, IFN-g, IL-6, or IL-17 cytokine
production by CD4þ T cells changed after treatment with
MR16-1 in Scl-cGVHD, splenic single-cell suspensions from
mice were stimulated for 4 hours. Splenic CD4þ T cells in
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Figure 3. Improved fibrosis scores in MR16-1-treated animals in the preventive model. Slides were scored and skin soluble collagen was measured as
described in Materials and Methods. (a) Representative photomicrographs of histopathological changes from syngeneic (BALB/c-BALB/c), control, and MR16-
1-treated groups. Sections were stained with hematoxylin and eosin (H&E) or Masson’s trichome. Arrows indicate the dermal thickness. Bar¼ 100mm.
Histopathological scores were analyzed at the end time point from (b) preventive and (c) therapeutic models. (d, e) Skin fibrosis was compared by determining
dermal thickness, (f) soluble collagen, and trichrome area/total area. (g) Lung and liver fibrosis was estimated by the ratio of trichrome area/total area. Each value
indicates mean (±SEM) results from four to five mice. *Po0.05, **Po0.01.
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MR16-1-treated animals had significantly reduced TNF-a
production compared with animals in the control group
(P¼0.04), whereas we observed no statistical differences in
IFN-g, IL-6, or IL-17 levels in the two groups (Figure 5d).
To determine whether skin cytokine/chemokine changes
after MR16-1 treatment in a preventive model, skin mRNA
expressions were assessed by real-time reverse transcrip-
tase PCR (RT–PCR). At 42 days after BMT, the mRNA
expressions of IL-2, IL-10, and IL-17A were similar in both
groups. By contrast, the expressions of IFN-g, TNF-a, IL-6,
IL-18, TGF-b1, CCL2, CCL3, and CCL5 were significantly
lower in the MR16-1-treated group than in the control
group (Figure 5e).
Anti-CD25 mAb treatment inhibited MR16-1’s attenuation in
Scl-cGVHD
To determine how depleting MR16-1-induced increase of
Tregs influences the Scl-cGVHD severity, Tregs were
depleted by intraperitoneal injection of anti-mouse CD25
mAb at days 0, 7, 21, and 35 in the MR16-1-treated group.
The number of splenic CD4þ T cells and CD4þFoxP3þ
T cells in the MR16-1þ anti-CD25-treated group were
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Figure 4. Elevated regulatory T cell (Treg) numbers in MR16-1-treated animals in the preventive model. Tregs in each experimental group. Total splenic
cellularity, absolute number of splenic CD4þ T cells, and Tregs are shown (a) 14 days and (b) 42 days following bone marrow transplantation (BMT) in the
preventive model, and (c) 57 days after BMT in the therapeutic model. CD1dhiCD5þCD19þ B cells in each experimental group. Absolute number of splenic
CD19þ B cells and CD1dhiCD5þCD19þ B cells (e) 14 days and (f) 42 days after BMT in the preventive model, and (g) 57 days after BMT in the therapeutic
model. Each value indicates mean (±SEM) results from four mice. *Po0.05.
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Figure 5. A decrease in tumor necrosis factor-a (TNF-a)-producing CD4þ T cells and low levels of TNF-a, IFN-c, IL-6, IL-18, TGF-b1, CCL2, CCL3, and
CCL5 mRNA in the preventive model. Splenic single-cell suspensions were stimulated as described in Materials and Methods. Percentages of IL-10-producing
CD19þ B cells from (a) preventive and (b) therapeutic models. (c) From the CD4þ T-cell gate, results represent one mouse from the MR16-1-treated group
or control group, indicating the percentages of TNF-a-producing CD4þ T cells with/without stimulation. (d) Cytokine production by CD4þ T cells in the
preventive model. (e) Expression of cytokine/chemokines was measured by real-time quantitative reverse transcriptase (RT–PCR) analysis. Each value indicates
mean (±SEM) results from four to five mice. *Po0.05, **Po0.01.
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significantly lower than that in the MR16-1-treated group
(0.46±0.15 106 and 0.49±0.19105 vs. 1.4±0.25106
and 2.27±0.38105, P¼0.016 and P¼0.006), and
similar to the control group (Figure 6d and e). Tregs
(CD4þCD25þFoxP3þ ) were mostly depleted by anti-CD25
mAb in the MR16-1þ anti-CD25 group. Thus, MR16-
1þ anti-CD25-treated group had an equivalent body weight
change and skin score to the control group and more body
weight loss and less skin score than the MR16-1-treated group
(Figure 6a and b).
Both MR16-1þ anti-CD25- and MR16-1-treated groups
have similar histopathological scores and dermal thickness
(6.86±0.63 vs. 7±0.58, P¼0.7816), which were higher
than those of the MR16-1 group (4.8±0.58). Skin trichrome
area ratios and soluble collagen levels also were significantly
higher in the MR16-1þ anti-CD25 and control group than in
the MR16-1 group (Figure 6c).
Therefore, anti-CD25 mAb treatment elicits that elevation
of Tregs is sufficient to demonstrate the effect of anti-IL6R
mAb on Scl-cGVHD.
DISCUSSION
In Scl-cGVHD, tissue damage results in the upregulation of
inflammatory mediators and chemoattractants in target tissues,
and in adhesion molecules in monocytes and donor-derived
T cells (Chu and Gress, 2008). Here, we show that MCP-1
increased 7 days post transplantation (Figure 1a), which
could promote infiltration of donor-derived mononuclear
cells, such as monocytes, activated macrophages, and T cells
into target tissues. Coincident with mononuclear cell infil-
tration, local host tissue damage leads to production of
proinflammatory cytokines, such as TNF-a (Figure 1a), that
augment the interaction between APCs, such as dendritic
cells and donor T cells (Levine, 2011).
Fibrotic changes of the skin and other organs including the
gastrointestinal tract, lung, and liver are the phenotypic
hallmarks in Scl-cGVHD, which are detectable B21 days
post transplantation (Claman et al., 1985; McCormick et al.,
1999). In contrast to autoantibody production observed in the
systemic lupus erythematosus cGVHD model, induction of
TGF-b1 and Th1 and Th2 cytokines is a specific characteristic
of Scl-cGVHD (Zhang et al., 2002; Zhou et al., 2007; Chu
and Gress, 2008). IFN-g is a prominent cytokine in the early
phase of murine Scl-cGVHD, confirmed by semiquantitative
RT-PCR analysis of total skin RNA on day 21 (Zhang et al.,
2002). In Scl-cGVHD cutaneous tissue, there is a mixed Th1/
Th2-like cytokine profile in early fibrosis with a Th1-like
predominance early and Th2-like profile later (Zhou et al.,
2007). In this study, we showed that serum Th1 cytokines
such as TNF-a and INF-g were present at high levels on day
28 post transplantation (Figure 1a).
Previous studies demonstrated an increase of serum and
target tissue IL-6 concentrations 7 days after allogeneic BMT
(Zhou et al., 2007; Chen et al., 2009; Tawara et al., 2011).
Similarly, we found a significant increase of serum IL-6 levels
(10-fold higher) 7 days post transplantation using anti-IL-6R
mAb (Figure 1b). Notably, serum IL-6 levels correlate with
cGVHD severity. Blockade of IL-6 signaling with anti-IL-6R
mAb demonstrated salutary effects in mouse models of
several inflammatory diseases (Serada et al., 2008). Although
serum IL-6 levels at later stages of Scl-cGVHD were increased
compared with those detected at early stages, our current
study indicates that blockade of IL-6 signaling reduces the
severity of Scl-cGVHD only if anti-IL-6R mAb is administered
during early stages of the disease (Figures 2 and 3). Using
blockade of IL-6 after Scl-cGVHD was already established
did not result in any changes of body weight or skin and
histopathological scores compared with administration of
control rat IgG. Moreover, we also demonstrated that IL-6 has
a role in disease pathogenesis only in early stages of cGVHD,
whereas IL-6 is present as a result of the inflammatory process
and fibrosis in later stages of the disease.
In the current study, the reduction of GVHD severity when
blocking IL-6 signaling early in the course of disease was
associated with increased numbers of Tregs (Figure 4a and b).
Prior studies support the idea that reconstitution of Tregs,
which have an important role in regulating T cell–mediated
transplantation tolerance, is severely impaired in both acute
and chronic GVHD (Zorn et al., 2005; Rieger, 2006; Chen
et al., 2007; Zhu et al., 2010). Blocking IL-6 binding to IL-6R
promotes an increase in the number of donor Tregs as a result
of peripheral Treg conversion (Chen et al., 2009). In our
study, an increase of Tregs appeared early after blockade of
IL-6 in Scl-cGVHD (Figure 4a). Recent studies have shown
that whereas IL-6 suppresses TGF-b1-induced Treg genera-
tion IL-6 and TGF-b1 promote the generation of Th17 cells
from naive T cells (Bettelli et al., 2006; Veldhoen et al., 2006;
Kimura et al., 2007). Interestingly, we found that IL-17-
producing CD4þ T cells and skin mRNA levels of IL-17A
were not different between MR16-1-treated and control
groups (Figure 5d and e). Furthermore, in our preventive
model, these results suggest that the increase in Treg numbers
results from early elevated TGF-b1 and blockade of IL-6
signaling. The effect of MR16-1 on Scl-cGVHD appeared
mostly inhibited by anti CD25 mAb (Figure 6). Thus, Tregs
that were reported to increase after using MR16-1 may have
an important role in attentuating the severity and fibrosis in
Scl-cGVHD.
Our current study demonstrates that IL-6 has an important
role in the pathogenesis of Scl-cGVHD. Therefore, blockade
of IL-6 may be an effective method for preventing Scl-cGVHD,
and may prove efficacious in the treatment of cGVHD and
scleroderma at early stages of disease in humans.
MATERIALS AND METHODS
Bone marrow transplantation
Eight- to twelve-week-old male B10.D2 (H-2d) and female BALB/c
(H-2d) mice were used as donors and recipients, respectively. Bone
marrow was T-cell depleted with anti-Thy1.2 microbeads (Miltenyi
Biotech, Auburn, CA). BALB/c recipients were irradiated with
800 cGy by an MBR-1520R machine (Hitachi, Tokyo, Japan). The
recipients were injected via the tail vein with 10 106 T-cell-
depleted bone marrow and 10 106 splenocytes in 0.5ml of
phosphate-buffered saline. The Committee on Animal Experimenta-
tion of Kanazawa University Graduate School of Medical Science
approved all studies and procedures.
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Figure 6. Anti-CD25 mAb treatment inhibited MR16-1’s attenuation in sclerodermatous chronic graft-versus-host disease (Scl-cGVHD). According to the
preventive model described in Materials and Methods, MR16-1-treated recipients were injected intraperitoneally with 250mg per mouse of anti-CD25
mAb at days 0, 7, 21, and 35. (a) Body mass changes and (b) skin scores were assessed every 3 days. (c) Histopathological skin score, dermal thickness,
skin trichrome area/total area, and skin soluble collagen were analyzed 42 days post bone marrow transplantation (BMT). (d) Representative of
CD4þCD25þFoxP3þ regulatory T cells (Tregs) and CD4þCD25þ T cells in each experimental group. (e) Absolute number of splenic CD4þ T cells,
(CD4þCD25þFoxP3þ ) Tregs, CD4þCD25þ T cells, and CD4þFoxP3þ T cells are shown. Each value indicates mean (±SEM) results from four to six mice.
*, #Po0.05, **, ##Po0.01.
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CBA and ELISA
Serum samples were obtained at 7, 14, 21, 28, and 35 days after
BMT. Serum IL-6, IL-10, MCP-1, IFN-g, TNF-a, IL-12p70, and
plasma TGF-b1 levels were measured by either the CBA Mouse
Inflammation Kit (BD Biosciences, San Jose, CA) or by the ELISA
mouse TGF-b1 kit (R&D systems, Minneapolis, MN) according to the
manufacturer’s instructions.
Flow cytometry
The following mAbs were used: FITC-, PE-, PE-Cy5-, PE-Cy7-, or
PerCP-Cy5.5-conjugated mAbs to mouse CD4 (RM4-5), CD19
(1D3), CD25 (MF-14), CD5 (53-7.3), CD1d (1B1) (BD Biosciences).
Splenic single-cell suspensions were stained for 20minutes for
two-, three-, or four-color immunofluorescence analysis at 4 1C using
mAbs at predetermined optimal concentrations. Intracellular staining
for FoxP3 (FJK-16 s, eBioscience, San Jose, CA) was performed using
the Cytofix/Cytoperm kit (BD Biosciences). Stained samples were
analyzed on a FACSVantage SE (BD Biosciences). Data were analyzed
using the FlowJo (Tree Star, Ashland, OR) software.
Reagents
MR16-1, a rat IgG1 mAb against the murine IL-6R, was provided
by Chugai Pharmaceutical (Tokyo, Japan). LEAF anti-mouse CD25
mAb (clone PC61) was obtained from BioLegend (San Diego, CA).
Control rat IgG, supplied by MP Biomedicals, LLC (Solon, OH),
was used as a control and was administered at the same dose and
times as MR16-1 and/or LEAF anti-mouse CD25 mAb. MR16-1
and control rat IgG1 were resuspended in phosphate-buffered
saline before injection.
Chronic GVHD
In the preventive model, recipients were injected intraperitoneally
with a loading dose of 2mg per mouse of MR16-1 or control rat IgG
on the day of BMT, and then injected weekly thereafter at a dose of
0.5mg per mouse for 6 weeks. In the therapeutic model, recipients
were injected intraperitoneally with a loading dose of 2mg per
mouse of MR16-1 or with control rat IgG on day 25 after BMT. Mice
were then injected weekly with 0.5mg antibody per mouse for 5
weeks. For depletion of Tregs, MR16-1-treated recipient mice were
injected intraperitoneally with 250 mg per mouse of anti-mouse
CD25 mAb at days 0, 7, 21, and 35.
Intracellular cytokine staining
Briefly, purified cell resuspensions (2 106 cells per ml) were
stimulated for 5 hours at 37 1C with lipopolysaccharide (10mgml1,
Sigma-Aldrich, St Louis, MO), phorbol 12-myristate 13-acetate
(50ngml1; Sigma-Aldrich), ionomycin (500ngml1; Sigma-Aldrich),
and monensin (2mM; eBioscience) for the detection of IL-10 pro-
duction by B cells, and stimulated for 4 hours at 37 1C with phorbol
12-myristate 13-acetate (50 ngml1), ionomycin (1 mgml1), and
brefeldin A (3 mM; BioLegend) for the detection of cytokine pro-
duction by T cells. After cell-surface staining with anti-CD19 mAb or
anti-CD4 mAb, the cells were washed, fixed, and permeabilized
using the Cytofix/Cytoperm Kit (BD Biosciences); cells were then
stained with propidium iodide–conjugated anti-IL-10 (JES5-16E3)
mAb from BioLegend or propidium iodide–conjugated anti-TNF-a
(MP6-XT22), IFN-g (XMG1.2), IL-6 (MP5-20F3), and IL-17A
(TC11-18H10) mAbs from eBiosciences.
Reverse transcriptase PCR
Total RNA was isolated from frozen skin specimens using RNeasy
spin columns (Qiagen, Hilden, Germany) and digested with DNase I
(Qiagen) to remove chromosomal DNA. Total RNA was reverse-
transcribed to a complementary DNA using a reverse transcription
system with random hexamers (Promega, Southampton, UK).
Cytokine mRNAs were analyzed using real-time RT–PCR quantifica-
tion (Applied Biosystems, Foster City, CA). Sequence-specific primers
and probes were designed with predeveloped TaqMan assay reagents
(Applied Biosystems). Real-time RT–PCR was performed on an ABI
Prism 7000 sequence detector (Applied Biosystems). GAPDH was
used to normalize the mRNA. The relative expression of real-time
RT–PCR products was determined according to the DDCt method to
compare target gene and GAPDH mRNA expression.
GVHD skin score
Clinical cGVHD score was modified as previously described
(Anderson, 2003). The following scoring system was used: healthy
appearance¼ 0; skin lesions with alopecia equal or less than 1 cm2
in area¼ 1; skin lesions with alopecia 1 to 2 cm2 in area¼ 2; skin
lesions with alopecia 2–5 cm2 in area¼ 3; skin lesions with alopecia
5–10cm2 in area¼ 4; skin lesions with alopecia 10–15cm2 in area¼ 5;
skin lesions with alopecia 15–20cm2 in area¼ 6; and skin lesions with
alopecia more than 20cm2 in area¼ 7. In addition, animals were
assigned 0.4 points for skin disease (lesions or scaling) on tail, and 0.3
points each for lesions on ears and paws. The minimum score was 0,
and the maximum score was 8. Final scores for dead animals were kept
in the data set for the remaining time points of the experiment.
Histological analysis
Skin samples taken from the interscapular region, lung, and liver were
fixed in 10% formalin and embedded in paraffin. Sections (6mm in
thickness) were stained with hematoxylin and eosin and Masson’s
trichrome for the detection of collagen deposition. Slides of skin were
scored by a dermatopathologist (blinded to experimental groups) on the
basis of epidermal interface changes, dermal collagen thickness,
mononuclear cell inflammation, subdermal fat loss, and follicular
dropout with scores from 0 to 2 for each category. The minimum score
was 0, and the maximum score was 10 (Anderson, 2003). Dermal
thickness was defined as the thickness of skin from the top of the
granular layer to the junction between the dermis and intradermal fat
(Tanaka et al., 2010). Collagen deposition was quantified on trichrome-
stained section as the ratio of blue-stained area to total stained area of
total staining using the Adobe Photoshop CS4 analysis tool.
Sircol soluble collagen assay
Total soluble collagen was quantified using the Sircol soluble
collagen assay (Biocolor, Newtownabbey, UK). Briefly, 6-mm skin
samples were homogenized in acid-pepsin solution (0.5 M acetic
acid containing 1mgml1 pepsin) over 2 nights at 4 1C. After
centrifugation, 1ml of Sircol dye was added to 100 ml of supernatant
and incubated for 30minutes. After removing the suspension,
droplets were dissolved in 1ml Sircol alkali reagent and relative
absorbance was measured at 555 nm.
Statistics
All data are shown as mean±SEM. The significance of differences
between sample means was determined with the Student’s t-test.
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